This article is more than 5 years old. Information may no longer be current.
Levolta granted patent for osteoarthritis treatment
Click Here to Manage Email Alerts
Levolta Pharmaceuticals announced recently that the U.S. Patent and Trademark Office has issued a patent for the company’s osteoarthritis therapy, VOLT01.
The novel formulation is a derivative of zoledronic acid that has demonstrated promise as a disease-modifying drug in clinical trials, according to a company press release.
The patent, U.S. 8,859,530, claims methods for treating OA through the intravenous administration of prednisone and zoledronic acid, or pharmaceutically acceptable salts thereof, in a single infusion, according to the release.
Although the patent claim does not limit the dosage of either aspect of the combination drug, a dependent claim specifies a dosage range of between 5 mg and 50 mg of prednisone, which comprises all considered dosages.
Noted side effects include flushing, fever, joint pain and muscle ache, according to the release.